LISTED digital medication management company MedAdvisor has announced an extension of its business to include supporting clinical trial recruitment, based on the company's level of patient connectivity.
With the clinical trial recruitment business valued at $2 billion worldwide, the company believes it can cut trial recruitment periods sufficiently to reduce lead time between drug discovery and drug marketability.
The upshot of faster recruitment is improved access to new medications and treatments, the company statement said.
MedAdvisor ceo Robert Read said, "We believe this is a win for patients and a win for innovative pharmaceutical and biotech companies who globally have struggled to find efficient methods of clinical trial recruitment.
"Given a patient life is fixed, the cost of each week of delay is one week at full global sales for that product before the patent ends, not to mention one week longer before patients can access therapy."
The MedAdvisor approach can also be "quite targeted" by geographical, demographical or site availability parameters and charge on a per eligible-patient fee basis.
The above article was sent to subscribers in Pharmacy Daily's issue from 11 Sep 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 11 Sep 18
